Soy isoflavone metabolite equol inhibits cancer cell proliferation in a PAP associated domain containing 5-dependent and an estrogen receptor-independent manner
0301 basic medicine
Estrogen Receptor alpha
Melanoma, Experimental
RNA Nucleotidyltransferases
Isoflavones
3. Good health
MicroRNAs
03 medical and health sciences
Equol
Receptors, Estrogen
Cell Line, Tumor
MCF-7 Cells
Humans
RNA, Small Nucleolar
Neoplasm Transplantation
Cell Proliferation
HeLa Cells
DOI:
10.1016/j.jnutbio.2021.108910
Publication Date:
2021-11-18T16:38:23Z
AUTHORS (8)
ABSTRACT
Isoflavone is a species of polyphenol found mainly in soy and soy products. Many studies have demonstrated its estrogen receptor (ER)-dependent action. Equol is an intestinal metabolite of a major soy isoflavone daidzein. We aimed to elucidate the mechanism for ER-independent actions of equol. Equol has been shown to inhibit proliferation of HeLa human cervical cancer cells and mouse melanoma B16 cells in an ER-independent manner. Using functional genetic screening, PAP associated domain containing 5 (PAPD5), which is a non-canonical poly(A) polymerase, was identified as an essential molecule in the ER-independent action. While peroral administration of equol inhibited tumor growth of control B16 cells subcutaneously inoculated in mice, it had little effect on the growth of PAPD5-ablated B16 cells. Intriguingly, equol progressed tumor growth of the PAPD5-ablated human breast cancer MCF-7 cells, which have high ERα expression. Equol has been found to induce polyadenylation of snoRNAs in a PAPD5-depdendent manner. Furthermore, peroral equol administration increased microRNA miR-320a expression in tumors. Together, these results suggest that equol may have a dual effect on ER-positive cancer cells, acting with, antiproliferative activity through PAPD5 and exhibiting proliferative activity via ERα and the former could be associated with miR-320a.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (44)
CITATIONS (19)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....